 <h1>Sulfisoxazole Side Effects</h1><ul class="nav-tabs nav-tabs-collapse nav-tabs-pill">
<li>Overview</li>
<li><b class="nav-item here">Side Effects</b></li>
<li>Dosage</li>
<li>Interactions</li>
<li>Pregnancy</li>
<li class="nav-more">
More&lt;svg aria-hidden="true" class="ddc-icon ddc-icon-down" focusable="false" height="16" viewbox="0 0 24 24" width="16" xmlns="http://www.w3.org/2000/svg"&gt;&lt;path d="M18.5 7.94L19.56 9 12 16.56 4.44 9 5.5 7.94l6.5 6.5z"&gt;&lt;/path&gt;&lt;/svg&gt;
</li>
</ul><ul>
<li>Managing Side Effects</li>
</ul><p><i>Applies to sulfisoxazole: compounding powder, oral suspension, oral tablet</i></p><h3>General</h3><p>In general, although not every side effect listed in the side effects section may have been reported with the use of sulfisoxazole, they have all been reported with the use of one or more sulfonamide compounds.</p><p></p><p>Sulfisoxazole was generally well tolerated.  Less than 0.1% of patients experienced serious side effects from sulfisoxazole.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Hypersensitivity side effects have included anaphylaxis, erythema multiforme (Stevens-Johnson syndrome), toxic epidermal necrolysis, angioedema, arteritis and vasculitis, serum sickness, conjunctival and scleral injection, generalized allergic reactions, and allergic myocarditis.<sup>[Ref]</sup></p><p>The use of sulfonamide antibiotics is associated with large increases in the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis, although these phenomena are rare as a whole.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Dermatologic side effects have included exfoliative dermatitis, rash, pruritus, photosensitivity, periarteritis nodosa, systemic lupus erythematosus, and generalized skin eruptions.<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Hematologic side effects have included agranulocytosis, leukopenia, thrombocytopenia, aplastic anemia, purpura, hemolytic anemia, eosinophilia, clotting disorders including hypoprothrombinemia, hypofibrinogenemia, sulfhemoglobinemia, and methemoglobinemia.<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Hepatic side effects have included hepatitis, hepatocellular necrosis, and jaundice.  Elevated liver-associated enzymes have been reported in patients with hepatitis.  Rare cases of hepatic necrosis have been associated with some sulfonamides.<sup>[Ref]</sup></p><h3>Renal</h3><p>Renal side effects have included elevated BUN and creatinine, acute renal failure, nephritis, and nephrosis with oliguria and anuria.  The frequency of renal complications is lower with the more soluble sulfonamides, such as sulfisoxazole.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p>Genitourinary side effects have included crystalluria, hematuria, and urinary retention.</p><h3>Cardiovascular</h3><p>Cardiovascular side effects have included tachycardia, palpitations, syncope, cyanosis, angioedema, arteritis, and vasculitis.</p><h3>Gastrointestinal</h3><p>Gastrointestinal side effects have included pseudomembranous colitis, nausea, emesis, anorexia, abdominal pain, diarrhea, gastrointestinal hemorrhage, melena, flatulence, glossitis, stomatitis, enlarged salivary gland, and pancreatitis.</p><p>Pseudomembranous colitis has occurred during or after sulfisoxazole therapy.</p><h3>Nervous system</h3><p>Nervous system side effects have included headache, dizziness, peripheral neuritis, paresthesia, convulsions, drowsiness, hearing loss, insomnia, tinnitus, vertigo, ataxia, and intracranial hypertension.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>Psychiatric side effects have included psychosis, hallucination, disorientation, depression, anxiety, and apathy.</p><h3>Other</h3><p>Other side effects have included edema (including periorbital), pyrexia, weakness, fatigue, lassitude, rigors, flushing, and chills.</p><h3>Respiratory</h3><p>Respiratory side effects have included cough, shortness of breath, pulmonary infiltrates, and pneumonitis.</p><h3>Musculoskeletal</h3><p>Musculoskeletal side effects have included arthralgia and myalgia.</p><h3>Endocrine</h3><p>Endocrine side effects have been reported rarely in patients receiving sulfonamides and have included goiter development, diuresis, and hypoglycemia.</p><p id="ref_1">1. "Multum Information Services, Inc. Expert Review Panel"  </p><p id="ref_2">2. Kounis GN,  Kouni SA,  Chiladakis JA,  Kounis NG "Comment: Mesalamine-Associated Hypersensitivity Myocarditis in Ulcerative Colitis and the Kounis Syndrome (February)." Ann Pharmacother 43 (2009): 393-4</p><p id="ref_3">3. Flach A, Peterson J, Mathias T "Photosensitivity to topically applied sulfisoxazole ointment." Arch Ophthalmol 100 (1982): 1286-7</p><p id="ref_4">4. Roujeau JC, Kelly JP, Naldi L, et al. "Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis." N Engl J Med 333 (1995): 1600-7</p><p id="ref_5">5. Flach A "Photosensitivity to sulfisoxazole ointment." Arch Ophthalmol 99 (1981): 609-10</p><p id="ref_6">6. "Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories, Nutley, NJ. </p><p id="ref_7">7. Boyer W, Lake C "Interaction of phenelzine and sulfisoxazole." Am J Psychiatry 140 (1983): 264-5</p><h2>More about sulfisoxazole</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Drug class: sulfonamides</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Advanced Reading</li>
</ul><h3>Professional resources</h3><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Bacterial Infection</li>
<li>Bladder Infection</li>
<li>Chancroid</li>
<li>Chlamydia Infection</li>
<li data-more-config-id="list-data-resources-conditions">... +10 more</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>